Status of progress of bulk drug parks in Gujarat

1. At a Glance

2. Why in the News

3. Background & Evolution

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic - Reduces API import dependence (≈70% of India's API demand sourced from China pre-2020); strengthens "Pharmacy of the World" positioning [S2][S3]. - Subsidised land + utilities (power, water, ETP, steam, solid waste, warehousing) cut unit-level capex/opex for API manufacturers [S2][S3].

Administrative - Centre funds CIF; states act through SIAs (GIDC in Gujarat). Of ₹600 crore released to GIDC in two ₹300 crore tranches, ₹341.44 crore utilised; ₹206.92 crore of ₹274.20 crore state share also utilised on CIF [S1]. - Civil tenders (roads, drainage, water, effluent collection, racks) awarded and largely completed on site; utility tenders (CETP, Solvent Recovery, TSDF) under execution [S1].

Environmental - API manufacturing is solvent- and effluent-intensive; mandatory CETP, Solvent Recovery and TSDF built into CIF [S1]. - Environmental Clearance under EIA Notification 2006 obtained in Feb 2024 — precondition for civil works [S1].

Strategic / Geopolitical - Part of Atmanirbhar Bharat pharma resilience stack alongside PLI (APIs/KSMs) and PLI 2.0 for pharma, reducing single-source vulnerability [S2].

6. Recent Developments (last 12-18 months)

7. Prelims Hooks

8. Mains Relevance

9. Related Topics to Study Next

10. Common Errors / Trap Areas

11. Sources